key: cord-0896580-5crabzs0
authors: Sivaloganathan, Helena; Ladikou, Eleni E; Chevassut, Timothy
title: COVID‐19 mortality in patients on anticoagulants and antiplatelet agents
date: 2020-06-25
journal: Br J Haematol
DOI: 10.1111/bjh.16968
sha: c167d27c2b3ad646db23aca0a505198d31d7c508
doc_id: 896580
cord_uid: 5crabzs0

Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D‐dimer and fibrinogen levels (Al‐Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID‐19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID‐19 (Klok, et al 2020, Stoneham, et al).

Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D-dimer and fibrinogen levels 3

(Al-Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID-19) caused by severe 4 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Extensive thrombosis in small vessels and 5 the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang, 6 et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised 7 COVID-19 patients can be as high as 25% (Songping, et al 2020) , and more recent studies have 8 indicated this can be expanded to other macrovascular thrombotic complications, such as a higher 9 than expected prevalence of pulmonary emboli in patients with COVID-19 (Klok, et al 2020, 10 Stoneham, et al). The term "diffuse pulmonary intravascular coagulopathy" has been proposed to 11 describe the lung-restricted vascular immunopathology associated with COVID-19. This is distinct 12 from disseminated intravascular coagulation in its early stages and is characterised by increased D-13 dimer with normal platelet count and normal/elevated fibrinogen (McGonagle, et al 2020). 14 Increased VTE rate has been associated with higher D-dimer level, and in the same study, an 15 association between VTE and death was found (Middeldorp, et al 2020) . Another study has shown 16 a D-dimer greater than 1 μg/mL was associated with a poorer prognosis (Zhou, et al 2020) . Patients 17 requiring mechanical ventilation who were treated with therapeutic anticoagulation had an in-18 hospital mortality of 29.1% compared to 62.7% in patients who did not receive anticoagulation.

Longer duration of anticoagulation was associated with a reduced risk of mortality (Paranjpe, et al 20 2020). 21

Trials comparing prophylactic with treatment dose anticoagulation in inpatients with COVID-19 have 22 been proposed and indeed will be studied as part of the "Randomized Embedded Multifactorial 23

Adaptive Platform for Community-acquired Pneumonia" (REMAP-CAP) Study. In this trial, the use of 24 low molecular-weight heparin or unfractionated heparin will be compared to standard pharmacologic 25 thromboprophylaxis (Angus, et al 2020) . It is still unknown, however, if pre-admission anticoagulation 26 might provide a protective benefit in COVID-19 infection. In theory, anticoagulants, or other 27 antithrombotic agents such as antiplatelet drugs, might counteract the coagulopathic effects of 28 COVID-19 resulting in improved outcomes in these patients. Based on this hypothesis, we investigated 29 the association between pre-admission antiplatelet/anticoagulant use and COVID-19 mortality. 30

The study population comprised those patients with confirmed COVID-19 based on a PCR-positive 31 SARS-CoV2 respiratory nasopharyngeal sample while admitted as an inpatient in Brighton and Sussex 32

University Hospitals NHS Trust between the 7 th of March and the 9 th of April. The case-control group 33 was constructed at a ratio of 1:2 cases to controls matching for age and sex, selecting from this overall 34 population. A case was defined as being on an anticoagulant or antiplatelet agent pre-admission. 35

Controls were then selected from the study population with a limited propensity matching by age 36 and sex to two controls who were not taking the medication of interest using a "nearest neighbour" 37 method. Data on patients' drug history was obtained using the Patient Administration System, which 38

was also used to identify patient deaths up to the 11 th May 2020. This work was carried out as part of 39 a service evaluation. Data collection and analysis were fully anonymized. Data was analysed using 40 SPSS software and plotted by Kaplan-Meier curves. Censored data represent end of follow up at 41 the time of ceasing data collection. 42

Two populations were analysed. The first group compared those who did (cases) and did not (controls) 43 take antiplatelet agents. The cases identified were 29, of which 62% (n=18) were on aspirin, 28% (n=8) 44 on clopidogrel, and 10% (n=3) on both. These were matched to controls (n=58). The second group 45 comprised 31 patients, who took anticoagulants, of which 23% (n=7) were on warfarin, 39% (n=12) 46 Accepted Article apixaban, 3% (n=1) dabigatran, 6% low molecular weight heparin (n=2), and 29% (n=9) rivaroxaban. 1 These were matched to controls (n=62). The mean (SD) age for the "Anticoagulant" and 2 "Antiplatelet" groups were 80 (9.2) and 79 (11.6) respectively. Being on either an anticoagulant or 3 antiplatelet agent pre-admission did not have a statistically significant effect on mortality in COVID-19 4 patients (p=0.614 and p=0.516 respectively, using the log-rank test), suggesting no protective effect 5 (Figures 1a and 1b) . However, the evident confounder in this analysis is the comorbidity of 6 cardiovascular disease, itself an established risk factor for increased mortality in COVID-19 7 (Matsushita, et al 2020) , and thrombotic disorders such as previous VTE or atrial fibrillation, that are 8 common indications for the prescription of these classes of drugs. In our data, we do not see any 9

increased mortality amongst cases suggesting that patients on antithrombotic agents have the same 10 mortality rate as patients not taking these agents. Of note, within the "anticoagulant" group, warfarin 11 use was seen to have an increased mortality risk on comparison of survival distributions, although 12 this was not statistically significant (p=0.42) ( figure 2a) . Similarly, within the "antiplatelet" group, 13 aspirin use was seen to have a reduced mortality risk, but again this was not statistically significant 14 (p=0.62) (figure 2b). Lastly, there was no difference in the percentage of patients admitted to ICU 15 between cases and controls in both the anticoagulant and antiplatelet groups (p=0.47 and 0.83 16 respectively) ( Table 1) . 17

To conclude, our study, though small, shows that patients taking antithrombotic therapy 18

(anticoagulant or antiplatelet agents) at the time of infection with COVID-19 do not have a 19

significantly different mortality risk to those patients not taking these drugs. This could suggest 20 these agents negate any potential increased mortality risk attributable to whichever disease the drugs 21 had been prescribed, but further data on comorbidities would be required to confirm this assertion. 22 There were trends towards lower mortality in patients on aspirin, and towards increased mortality in 23 patients on warfarin, but the limited sample size meant that these did not reach statistical significance. 24

Trials are ongoing to assess the role of anticoagulation in the care of patients with COVID-19 as 25

inpatients. In addition, our data suggests that larger scale investigation of pre-admission 26 anticoagulants or antiplatelet agents is needed, preferably adjusting for potential confounders such 27 as cardiovascular disease, to establish the optimal protection of patients from the microangiopathic 28 and thrombotic complications seen in COVID-19. 29 Figure 1a : Kaplan Meier plot of COVID-19 inpatients who were on anticoagulation pre-admission 2 versus those who were not. 

COVID and Coagulation: 3 Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection

The Randomized Embedded Multifactorial Adaptive Platform 6 for Community-acquired Pneumonia (REMAP-CAP) study: rationale and design

Confirmation of the High Cumulative Incidence 10 of Thrombotic Complications in Critically Ill ICU Patients With COVID-19: An Updated 11 Analysis

The relationship of COVID-19 severity with cardiovascular disease and its traditional 14 risk factors: A systematic review and meta-analysis. medRxiv

Immune mechanisms of 17 pulmonary intravascular coagulopathy in COVID-19 pneumonia

Incidence of venous thromboembolism in 20 hospitalized patients with COVID -19

Association of Treatment Dose Anticoagulation 24 With In-Hospital Survival Among Hospitalized Patients With COVID-19

Prevalence of venous thromboembolism 27 in patients with severe novel coronavirus pneumonia

Thrombotic Risk in COVID-19: a case 31 series and case-control study

Abnormal coagulation parameters are associated with poor 33 prognosis in patients with novel coronavirus pneumonia

Comparison of clinical and pathological features between 35 severe acute respiratory syndrome and coronavirus disease

Clinical course and risk factors 39 for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 40 study